Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 6;204(1):8.
doi: 10.1007/s00203-021-02606-x.

COVID-19: comprehensive review on mutations and current vaccines

Affiliations
Review

COVID-19: comprehensive review on mutations and current vaccines

Ananda Vardhan Hebbani et al. Arch Microbiol. .

Abstract

Viral outbreaks had been a threat for the human race for a long time. Several epidemics and pandemics have been reported in the past with serious consequences on human health and subsequent social and economic aspects. According to WHO, viral infections continue to be a major health concern globally. Novel coronavirus, SARS-CoV-2 (Severe acute respiratory syndrome coronavirus-2) causes the most recent infectious pandemic disease, COVID-19 (Coronavirus disease-19). As of now, there were 249 million infections of COVID-19 worldwide with a high mortality of more than 5 million deaths reported; and the number of new additional cases is drastically increasing. Development of therapies to treat the infected cases and prophylactic agents including vaccines that are effective towards different variants are crucial to curtail the COVID-19 pandemic. Owing to the fact that there is a high mortality and morbidity rate along with the risk of virus causing further epidemic outbursts, development of additional effective therapeutic and preventive strategies are highly warranted. Prevention, early detection and treatment will reduce the spread of COVID-19 pandemic. The present review highlights the novel mutations and therapeutic updates associated with coronaviruses along with the clinical manifestations-diagnosis, clinical management and, prophylactic and therapeutic strategies of COVID-19 infection.

Keywords: COVID-19; Clinical management; Mutations; SARS-CoV-2; Therapeutic strategies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Genetic lineage of Corona family
Fig. 2
Fig. 2
Genetic lineage of Corona viruses

Similar articles

Cited by

References

    1. Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, Kim BT, Kim SJ. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19) J Microbiol Biotechnol. 2020;30(3):313–324. doi: 10.4014/jmb.2003.03011. - DOI - PMC - PubMed
    1. Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva-O'Callaghan A, Pardos-Gea J, Quintana A, Mekinian A, Anunciacion-Lunell A, Miró-Mur F. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: a comprehensive review. Autoimmun Rev. 2020 doi: 10.1016/j.autrev.2020.102569. - DOI - PMC - PubMed
    1. Amawi H, Abu Deiab GI, Aljabali AA, Dua K, Tambuwala MM. COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics. Ther Deliv. 2020;11(4):245–268. doi: 10.4155/tde-2020-0035. - DOI - PMC - PubMed
    1. Ang L, Lee HW, Choi JY, Zhang J, Lee MS. Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines. Integr Med Res. 2020;9:100407. doi: 10.1016/j.imr.2020.100407. - DOI - PMC - PubMed
    1. Badri KR, Aramgam S, Muppurum MK, Kona A, Kona A. Efficacy of Tinospora cordifolia in treating SARS-CoV-2: in silico studies. FASEB J. 2021;35(1):4976. doi: 10.1096/fasebj.2021.35.S1.04976. - DOI